IP Library › Granted Patent US 8,058,310
Granted Patent B2
US 8,058,310 · App. 12/660,351 · Granted Nov 15, 2011

Polyphenol proteasome inhibitors, synthesis, and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,058,310
App. No.
12/660,351
Granted
Nov 15, 2011
Kind
B2
Abstract

The present invention relates to synthetic green tea derived polyphenolic compounds, their modes of syntheses, and their use in inhibiting proteasomal activity and in treating cancers. The present invention is also directed to pharmaceutical compositions useful in methods of inhibiting proteasomes and of treating cancers.

Claims (20)

1. A method of a) increasing the relative proportion of cells occupying the G 1 phase of the mitotic cell cycle within prostate tumor or cancer cells and leukemia cells; or b) inducing apoptosis in prostate tumor or cancer cells and leukemia cells; said method comprising contacting the prostate tumor or cancer cells and leukemia cells with an effective amount of a compound having a formula of:

or a pharmaceutically acceptable salt of said compound; or a composition comprising said compound, or a pharmaceutically acceptable salt of said compound.

2. The method according to claim 1 , wherein said cells are human cells.

3. The method according to claim 1 , wherein said contacting occurs in vivo, and said contacting comprises administering the compound to a patient by a route selected from the group consisting of orally, parenterally, subcutaneously, intravenously, intramuscularly, intraperitoneally, intraarterially, transdermally, and via a mucus membrane.

4. The method according to claim 1 , wherein said contacting occurs in vitro.

5. The method according to claim 1 , wherein said compound has less than 100% optical purity.

6. The method according to claim 1 , wherein said compound is optically pure.

7. The method according to claim 1 , wherein said composition comprises a pharmaceutically acceptable carrier or diluent.

8. The method according to claim 1 , wherein said compound has the formula of:

or a pharmaceutically acceptable salt of said compound; or a composition comprising said compound, or a pharmaceutically acceptable salt of said compound.

9. The method according to claim 1 , wherein said compound has the formula of:

or a pharmaceutically acceptable salt of said compound; or a composition comprising said compound, or a pharmaceutically acceptable salt of said compound.

10. The method according to claim 1 , wherein said compound has the formula of:

or a pharmaceutically acceptable salt of said compound; or a composition comprising said compound, or a pharmaceutically acceptable salt of said compound.

11. The method according to claim 1 , wherein said compound has the formula of:

or a pharmaceutically acceptable salt of said compound; or a composition comprising said compound, or a pharmaceutically acceptable salt of said compound.

12. The method according to claim 1 , wherein said compound has the formula of:

or a pharmaceutically acceptable salt of said compound; or a composition comprising said compound, or a pharmaceutically acceptable salt of said compound.

13. The method according to claim 1 , wherein said cells are prostate tumor or cancer cells.

14. The method according to claim 1 , wherein said cells are leukemia cells.